Menicon stock came into this print on a strong short term run, with double digit gains over 7, 30 and 90 days. Yet the real story sits in the profit line rather than the chart. Q1 FY2027 delivered net income of ¥2,230m and basic EPS of ¥30.04, a clean swing away from the loss reported in Q4 FY2026 on similar revenue levels. For a contact lens and eye care stock often judged on growth expectations and a premium P/E, this quarter is about how much earnings power actually showed up in cash terms.
Love Menicon's sharp swing back into profit but unsure if that earnings power is durable enough for your portfolio? Check out 56 resilient stocks with low risk scores to compare it with companies that have steadier fundamentals and lower risk scores.
Prefer clear charts over scrolling through lines of financial figures and earnings tables? See Menicon's full financial picture in an easy visual format, including a breakdown of its valuation and earnings profile, in the company report for Menicon.
For investors who see Menicon as a defensive vision care stock, this quarter gives that view some backing. Revenue reached ¥32,376m with net income at ¥2,230m and basic EPS at ¥30.04, all higher than a year earlier. The step up in trailing 12 month net income to ¥7,155m supports the idea of a business that can translate recurring lens and care demand into profit. Recent double digit share price gains over 7, 30 and 90 days show that the market has been leaning into that improvement.
The swing from a loss in Q4 FY2026 to profit in Q1 FY2027 also flags a key risk for Menicon. Earnings look sensitive to relatively small shifts in revenue or cost mix. That matters in a competitive global contact lens market where larger rivals can pressure pricing. Even with higher year on year revenue and earnings, the recent loss is a reminder that profit stability is not guaranteed each quarter. Investors who focus on margin pressure and earnings swings can still find support for a more cautious stance.
Reveal where the surface looks calm, but the models start to disagree on Menicon's next few years and what the street is quietly building into revenue and EPS projections. Access the full multi year analyst estimates for Menicon.If Menicon's sharp earnings rebound has your attention, register for free with Simply Wall St and add it to a Watchlist to track its share price against fair value and watch for a more compelling entry point. Once you decide to take a position, use the Portfolio Command Center to cut through market noise and focus on the most important developments affecting your holdings. For a broader view, tap into the Community to see what other investors are thinking and which issues they are watching most closely. This is how you spot potential catalysts and risks early and stay a step ahead of the market.
Fresh ideas move first as breakouts build momentum and early signals risk getting caught by the crowd. Scan under the radar for now while it matters and act now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com